Answers are grounded in this paper and cite their sources.
Recombinant enzyme improves function in genetic disorders, suggesting PEGylation and glycosylation enhance efficacy.
Amino Acid Sequence: The MEQ Recombinant Enzyme is designed to replace deficient or malfunctioning enzymes in patients with genetic disorders. The sequence is tailored for optimal activity and stability, with specific focus on the catalytic domain responsible for the enzyme’s function. Modifications: The enzyme may be PEGylated to enhance its stability and prolong its circulation time in the bloodstream. Other modifications, such as glycosylation, are considered to improve solubility and reduce immunogenicity, ensuring that the enzyme is more effective in vivo.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: